Russian Heart Failure Journal 2008year Heart injury in hypereosinophilic syndrome


To access this material please log in or register

Register Authorize
2008/

Heart injury in hypereosinophilic syndrome

Storozhakov G.I.

Keywords:

DOI:

    1.    Topol EJ, Textbook of Cardiovascular Medicine, 2nd edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2002.
    2.    Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8th edition. Elsevier, Philadelphia, PA, 2007.
    3.    Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147–174.
    4.    Desreumaux P, Capron M. Eosinophils in allergic reactions. Curr Opin Immunol. 1996;8 (6):790–795.
    5.    Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83 (10):2759–2779.
    6.    Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341 (15):1112–1120.
    7.    Roufosse F, Schandene L, Sibille C et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000;109 (3):540–548.
    8.    Morgan SJ, Prince HM, Westerman DA et al. Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich’s syndrome). Leuk Lymphoma. 2003;44 (9):1623–1625.
    9.    Zenone T, Felman P, Malcus C, Durieu I, Durand DV. Indolent course of a patient with hypereosinophilic syndrome associated with clonal T-cell proliferation. Am J Med. 1999;107 (5):509–511.
    10.    Klion AD, Noel P, Akin C et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101 (12):4660–4666.
    11.    Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982;97 (1):78–92.
    12.    Klion AD, Robyn J, Akin C et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103 (2):473–478.
    13.    Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P. Clinical and molecular features of FIP1L1‑PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18 (4):734–742.
    14.    Liapis H, Ho AK, Brown D et al. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int. 2005;67 (5):1806–1811.
    15.    Pardanani A, Ketterling RP, Brockman SR et al. CHIC2 deletion, a surrogate for FIP1L1‑PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102 (9):3093–3096.
    16.    Score J, Curtis C, Waghorn K et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 2006;20 (5):827–832.
    17.    Isselbacher K, Braunwald E, Wilson J, Martin J, Fauci A, Kasper D. Harrison’s principles of internal medicine, thirteenth edition, companion handbook, McGraw-Hill Inc., New York, 1994 – p. 833..
    18.    Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8th edition. Elsevier, Philadelphia, PA, 2007.

To access this material please log in or register

Register Authorize
Ru En